Publication Name	World Journal of Gastroenterology
Manuscript ID	14030
Country	Germany

Received	2014-09-15 13:51
Peer-Review Started	2014-09-15 20:44
To Make the First Decision	2014-10-14 16:55
Return for Revision	2014-10-17 08:23
Revised	2014-10-24 21:31
Second Decision	2014-11-18 10:56
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-12-01 13:43
Articles in Press	2014-12-01 14:03
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-03-07 17:00
Publish the Manuscript Online	2015-03-19 16:57

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Study
Article Title	Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis
Manuscript Source	Unsolicited Manuscript
All Author List	Enayatullah Baki, Philipp Zwickel, Anna Zawierucha, Robert Ehehalt, Daniel Gotthardt, Wolfgang Stremmel and Annika Gauss
Funding Agency and Grant Number
Corresponding Author	Annika Gauss, MD, Division of Gastroenterology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. annika.gauss@med.uni-heidelberg.de
Key Words	Inflammatory bowel disease; Tumor necrosis factor α inhibitors; Ulcerative colitis; Outcome; Real life
Core Tip	Tumor necrosis factor alpha inhibitors are a widely accepted therapeutic option for the treatment of ulcerative colitis. Results from different real-life settings on their use in ulcerative colitis are controversial. Weighing anti tumor necrosis factor alpha against other treatment options, it is very important to decide on the best therapy for a patient. This retrospective study from a tertiary referral centre shows a rate of steroid-free clinical remission of 22.2% and a colectomy rate of 20.8% for ambulatory patients with ulcerative colitis under therapy with tumor necrosis factor alpha inhibitors. These rather disappointing outcomes should be thoroughly discussed with the patients before start of therapy.
Publish Date	2015-03-19 16:57
Citation	Baki E, Zwickel P, Zawierucha A, Ehehalt R, Gotthardt D, Stremmel W, Gauss A. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis. World J Gastroenterol 2015; 21(11): 3282-3290
URL	http://www.wjgnet.com/1007-9327/full/v21/i11/3282.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i11.3282

Full Article (PDF)	WJG-21-3282.pdf
Full Article (Word)	WJG-21-3282.doc
Manuscript File	14030-Review.DOC
Answering Reviewers	14030-Answering reviewers.pdf
Biostatistics Review Certificate	Biostatistician_Review_Report_20140914224522.pdf
Copyright License Agreement	14030-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	Ethics_Committee_20140914224436.pdf
Non-Native Speakers of English Editing Certificate	14030-Language certificate.pdf
Peer-review Report	14030-Peer review(s).pdf
Scientific Misconduct Check	14030-CorssCheck.jpg
Scientific Editor Work List	14030-Scientific editor work list.pdf